Dr. Cromwell has over 30 years of senior executive and technical expertise in numerous hi-tech industries. He has piloted the design, development, and manufacture of systems for biological assays, materials analysis, optical inspection, and process control. Prior to Protein Fluidics, Evan served as the President and CEO of California-based Blueshift Biotechnologies. This high-content screening and analysis venture was acquired by Molecular Devices in 2008. After the acquisition, Evan remained onboard at Molecular Devices, which became part of Danaher Life Sciences, where he further honed his business and entrepreneurial acumen. In addition to co-founding successful start-ups, Evan has chaired several scientific advisory boards and led global technology development initiatives. Evan’s passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities.

Evan holds a B.S. in Chemistry from Caltech and earned his Ph.D. in Physical Chemistry in the laboratory of Nobel Laureate Yuan-Tseh Lee at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 17 patents.